BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Lowered to $13.00 at Royal Bank Of Canada

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective cut by investment analysts at Royal Bank Of Canada from $14.00 to $13.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada’s price objective suggests a potential upside of 99.85% from the company’s previous close.

A number of other brokerages also recently issued reports on BCRX. Needham & Company LLC cut their price target on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, November 4th. JMP Securities increased their price objective on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a research report on Wednesday, October 15th. Citizens Jmp decreased their target price on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a research note on Wednesday, November 5th. HC Wainwright increased their target price on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Finally, Cantor Fitzgerald upped their price target on shares of BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 15th. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX traded down $0.17 during trading hours on Friday, hitting $6.51. 713,204 shares of the company were exchanged, compared to its average volume of 4,819,386. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -130.10, a PEG ratio of 0.36 and a beta of 0.80. BioCryst Pharmaceuticals has a 52-week low of $6.00 and a 52-week high of $11.31. The company’s 50 day moving average price is $7.28 and its 200-day moving average price is $7.61.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative net margin of 1.46% and a negative return on equity of 4.24%. The firm had revenue of $159.40 million during the quarter, compared to analysts’ expectations of $162.91 million. During the same quarter last year, the business earned ($0.07) EPS. The business’s revenue was up 36.1% compared to the same quarter last year. On average, equities analysts predict that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

Insider Activity at BioCryst Pharmaceuticals

In related news, insider Alane P. Barnes sold 91,004 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $7.10, for a total value of $646,128.40. Following the completion of the transaction, the insider owned 416,152 shares of the company’s stock, valued at $2,954,679.20. This represents a 17.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 183,453 shares of company stock worth $1,330,965. 5.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in BCRX. Focus Partners Wealth acquired a new stake in BioCryst Pharmaceuticals in the third quarter valued at $77,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 2,115 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in shares of BioCryst Pharmaceuticals by 326.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 8,109 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in shares of BioCryst Pharmaceuticals during the 3rd quarter worth approximately $81,000. Finally, Vestmark Advisory Solutions Inc. acquired a new position in BioCryst Pharmaceuticals in the 3rd quarter valued at $81,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.